Bionano Genomics (NASDAQ:BNGO) just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is getting leaner while its technology goes deeper into the clinical mainstream.

Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday’s regular session.

The Financials: Narrowing the Gap

For the fourth quarter, Bionano reported revenue of $8 million, landing at the high end of its previous guidance. While this was a 3% decrease from the prior year, the real victory was in the margins. Full-year gross margins skyrocketed to 46%, a massive leap from the 1% seen in 2024.

The improvement stems from a strategic shift toward recurring revenue. Bionano is focusing on its core “routine users” of Optical Genome Mapping (OGM) and VIA software.

By cutting operating expenses by roughly 55%, the company is aggressively tackling its cash burn to extend its runway, ending the year with $29.6 million in liquidity.

Market Momentum and OGM Adoption

The stock’s recent movement has been buoyed by more than just balance sheets. Scientific adoption is hitting an inflection point:

  • Reimbursement Wins: A 47% increase in the 2026 Clinical Lab Fee Schedule for OGM in hematologic malignancies is now in effect, providing a direct tailwind for hospital adoption.
  • Clinical Evidence: At the 2026 ACMG Annual Meeting, OGM studies saw a two-fold increase compared to last year, signaling that the medical community is increasingly viewing OGM as the “gold standard” for structural variant analysis.

What's Next for BNGO?

Wall Street remains cautiously optimistic. While the stock has faced heavy pressure over the last year, analysts maintain a consensus price target far above current levels — ranging from $4 to more than $7 — citing the massive upside if OGM continues to displace traditional cytogenetics.

With a first-quarter 2026 revenue guide of $6.5 million to $6.7 million, Bionano is betting that its “leaner and meaner” structure will finally allow the stock to map out a sustainable recovery.

BNGO Stock Price: According to data from Benzinga Pro, Bionano Genomics shares closed Monday up 26.96% at $1.46; after-hours trading was slightly down.

Photo: Shutterstock